Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, has entered a multi-year research collaboration agreement with Merck, to discover novel drug targets in inflammatory bowel disease (IBD) using Quotient’s somatic genomics platform technology. Somatic genetic mutations naturally accumulate over a lifetime, resulting in trillions of different genomes within an individual. Through its platform, Quotient interrogates patient tissue for these mutations w...